Avid Bioservices Inc (CDMO)

[biopharm]

Friends or relatives or highest paying may get something.... current BODs failed theiir fiduciary Duties bigtime and easy to see

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=119618782

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=120042189

Laura E. Benjamin
https://www.linkedin.com/in/laura-e-benjamin-04299b34


Profile picture
Laura E Benjamin
Eli Lilly (Germany)
Bad Homburg, Germany


Brief Bio
Laura Benjamin received a B.A. in Biology from Barnard College, Columbia University in 1987, and a PhD in Molecular Biology at the University of Pennsylvania in 1995. Her graduate thesis characterized a novel chromosomal translocation between the EWS1 Ewings sarcoma gene and the WT1 Wilms’ tumor suppressor gene in pediatric cancer under the guidance of Dr. Frank Rauscher at the Wistar Institute. During her postdoctoral fellowship with Eli Keshet, she pioneered fundamental principles in the field of tumor angiogenesis relating to VEGF-A survival functions and the role of pericytes in sensitivity and resistance to VEGF antagonism. In 1999 she started a research lab as Assistant professor and in 2005 she was promoted to Associate Professor in the Department of Pathology, Harvard Medical School. There she ran several NIH-funded research programs investigating molecular mechanisms of angiogenesis and cancer biology. From 2007-2009, Laura served as Associate Director of the Beth Israel Center for Vascular Biology Research (CVBR) where she gained experience in the scientific mentoring of junior faculty across a diversity of vascular biology topics from cancer to diabetes to thrombosis. Over the years Laura has served on multiple national and international grant review committees including a 4-year appointment to the NIH Tumor Microenvironment review panel. She has been active in journal peer review served on several editorial boards. In July 2009, Laura joined ImClone Systems, a wholly owned subsidiary of Eli Lilly as a Vice President in the research divison. As a part of the ImClone/Lilly Research Oncology Division, Laura leads the Angiogenesis Efforts as an integrated team focused from target identification to biomarker development and late stage asset support and serves on advisory and managerial boards serving the greater oncology porfolio. At the present time she also serves as a Senior Editor for Cancer Research.

https://loop.frontiersin.org/people/32468/bio

______________

http://cenoxsys.com/intellectual_property_and_publications

9 Deer Park Drive
Suite K
Monmouth Jct, NJ 08852
ph: 908-783-0338
fax: [phone]
[e-mail]

Core Competencies:
Corporate development
Screening Assay development
Neurobiology and CNS drug discovery
General Pharmacology and preclinical drug development
Advanced Computational Chemistry
In vivo and ex vivo animal model development
Clinical trial design and Statistics
Biomarker Development, Validation,and Monitoring

Intellectual Property
Osteocalcin and analogs thereof. Benjamin, D: May 25, 2014 US 62/002,403
This is a patent on analogs of osteocalcin and its fragments optimized for improved pharmocokinetics, decreased immunogenicity, and enhanced efficacy for use as an antinflammatory in trauma, spinal degenerative disease and rheumatoid arthritis, and in diabetes.

?

Publications
Lange DJ, Andersen, PM, Marklund, S, Benjamin D: Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: A phase I pilot study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013; 14: 199–204

Benjamin D: Identification of pyrimethamine as an inhibitor of SOD-1 expression at the protein level. In preparation.

Patterson-Buckendahl, P, Sowinska A, Yee S, Patel D, Pagkalinawan S, Shahid M, Shah A, Franz C, Benjamin D, Pohorecky LA: Decreased sensory responses in osteocalcin null mutant mice imply neuropeptide function. Cell Mol Neurobiol. 2012 Jul;32(5):879-89.

http://cenoxsys.com/intellectual_property_and_publications

_____


Daniel E. Benjamin
https://www.linkedin.com/in/daniel-e-benjamin-ph-d-8563961

Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition ....

What the hell did the new BODs do with strategic Biomarker data that were assets to Peregrine ?

https://www.selfhacked.com/blog/osteocalcin/